WO2023059064A1 - 자연살해 세포의 활성 향상용 조성물 - Google Patents
자연살해 세포의 활성 향상용 조성물 Download PDFInfo
- Publication number
- WO2023059064A1 WO2023059064A1 PCT/KR2022/014996 KR2022014996W WO2023059064A1 WO 2023059064 A1 WO2023059064 A1 WO 2023059064A1 KR 2022014996 W KR2022014996 W KR 2022014996W WO 2023059064 A1 WO2023059064 A1 WO 2023059064A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- natural killer
- cells
- cancer
- killer cells
- peptide
- Prior art date
Links
- 210000000822 natural killer cell Anatomy 0.000 title claims abstract description 103
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 16
- 210000004027 cell Anatomy 0.000 claims abstract description 133
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 88
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 63
- 201000011510 cancer Diseases 0.000 claims abstract description 60
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 46
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims abstract description 42
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims abstract description 42
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims abstract description 42
- 230000000694 effects Effects 0.000 claims abstract description 39
- 230000022534 cell killing Effects 0.000 claims abstract description 20
- 239000004480 active ingredient Substances 0.000 claims abstract description 19
- 230000001093 anti-cancer Effects 0.000 claims abstract description 13
- 230000035945 sensitivity Effects 0.000 claims abstract description 9
- 239000002671 adjuvant Substances 0.000 claims abstract description 4
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 4
- 239000002157 polynucleotide Substances 0.000 claims description 33
- 102000040430 polynucleotide Human genes 0.000 claims description 33
- 108091033319 polynucleotide Proteins 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 238000002659 cell therapy Methods 0.000 claims description 4
- 208000037819 metastatic cancer Diseases 0.000 claims description 4
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 description 18
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 16
- 201000005202 lung cancer Diseases 0.000 description 16
- 208000020816 lung neoplasm Diseases 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 16
- 239000001963 growth medium Substances 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 11
- 230000002147 killing effect Effects 0.000 description 10
- 239000012636 effector Substances 0.000 description 9
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 8
- 102000001398 Granzyme Human genes 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 108060005986 Granzyme Proteins 0.000 description 6
- 102000014150 Interferons Human genes 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 229940079322 interferon Drugs 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108010056995 Perforin Proteins 0.000 description 5
- 102000004503 Perforin Human genes 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 4
- 239000002543 antimycotic Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 201000005787 hematologic cancer Diseases 0.000 description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 229930192851 perforin Natural products 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 108091008042 inhibitory receptors Proteins 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- -1 amino acids Amino acids Chemical class 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 102100038077 CD226 antigen Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 108090000567 Caspase 7 Proteins 0.000 description 1
- 102100026549 Caspase-10 Human genes 0.000 description 1
- 108090000572 Caspase-10 Proteins 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102100038902 Caspase-7 Human genes 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- 108010049207 Death Domain Receptors Proteins 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- 102100038393 Granzyme H Human genes 0.000 description 1
- 101710113220 Granzyme H Proteins 0.000 description 1
- 108050003624 Granzyme M Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102100022469 Interferon kappa Human genes 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101150030213 Lag3 gene Proteins 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100021285 Macrophage-expressed gene 1 protein Human genes 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 1
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 1
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 1
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 1
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 206010046392 Ureteric cancer Diseases 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 201000003761 Vaginal carcinoma Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000011523 endocrine gland cancer Diseases 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 201000001343 fallopian tube carcinoma Diseases 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 201000003911 head and neck carcinoma Diseases 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 108010080375 interferon kappa Proteins 0.000 description 1
- 108010045648 interferon omega 1 Proteins 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000029559 malignant endocrine neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 108010091748 peptide A Proteins 0.000 description 1
- 108010052036 perforin 2 Proteins 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000023750 transforming growth factor beta production Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000004916 vulva carcinoma Diseases 0.000 description 1
- 208000013013 vulvar carcinoma Diseases 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Definitions
- the present invention relates to a composition for improving the activity of natural killer cells, and more particularly, to a composition for restoring the reduced activity of natural killer cells by TGF- ⁇ .
- Natural killer cells are lymphocytes present in bone marrow, lymph nodes, and peripheral blood, and account for about 10 to 15% of all lymphocytes. Phenotypes are CD3-negative and CD56-positive, and as immune cells equipped with the ability to kill cancer cells or virus-infected cells, they play an important role in the innate immune response. The function of natural killer cells is regulated by the interaction between cell surface receptors and corresponding target cell ligands without stimulation of specific antigens, and these receptors are largely divided into active receptors and inhibitory receptors.
- Active receptors that regulate the function of natural killer cells by transmitting activation signals to natural killer cells include natural cytotoxicity receptors (NCRs) such as NKp30, NKp44, and NKp46, NKG2D, and the like.
- NCRs natural cytotoxicity receptors
- Activated natural killer cells can destroy target cells by synthesizing various granules and secreting them out of the cells.
- Perforin and Granzyme play a major role in destroying target cells. Perforin gathers on the cell membrane of the target cell to form a complex to open a hole in the cell membrane to cause cell lysis. by inducing cell death.
- natural killer cells induce apoptosis of cancer cells by binding to death receptors of cancer cells using death ligands such as FasL and TRAIL.
- death ligands such as FasL and TRAIL.
- the binding of these receptors activates caspase-8 and caspase-10 in cancer cells, which activates caspase-3 and caspase-7, resulting in apoptosis.
- TGF- ⁇ is a cytokine with immunosuppressive activity and suppresses the anticancer activity of T cells or natural killer cells.
- TGF- ⁇ is produced and secreted to suppress the immune function in the microenvironment of cancer, thereby helping the growth of cancer tissues.
- TGF- ⁇ secretion in metastatic cancer is closely related to poor cancer prognosis.
- inhibition of TGF- ⁇ production or signaling enhances the anticancer activity of natural killer cells.
- TGF- ⁇ suppresses the production of IFN- ⁇ of natural killer cells and suppresses the killing ability by CD16.
- An object of the present invention is to provide a composition capable of enhancing the activity of natural killer cells.
- the present invention provides a composition for enhancing the activity of natural killer cells, comprising a peptide having the amino acid sequence of SEQ ID NO: 1 or a polynucleotide encoding the same as an active ingredient.
- the present invention provides a pharmaceutical composition for preventing or treating cancer comprising a peptide having the amino acid sequence of SEQ ID NO: 1 or a polynucleotide encoding the same as an active ingredient.
- the present invention provides a cell therapy agent for preventing or treating cancer, including natural killer cells treated with a peptide having the amino acid sequence of SEQ ID NO: 1 or a polynucleotide encoding the same.
- the present invention provides a method for enhancing the activity of natural killer cells, comprising treating natural killer cells with a peptide having the amino acid sequence of SEQ ID NO: 1 or a polynucleotide encoding the same.
- the present invention provides a cancer treatment method comprising the step of administering to a subject in need of treatment a pharmaceutical composition for preventing or treating cancer comprising a peptide having the amino acid sequence of SEQ ID NO: 1 or a polynucleotide encoding the same. .
- the present invention comprises the steps of (a) treating natural killer cells with a peptide consisting of the amino acid sequence of SEQ ID NO: 1 or a polynucleotide encoding the same; and (b) administering the natural killer cells of step (a) to a subject.
- the present invention provides a pharmaceutical composition for preventing or treating cancer comprising a peptide having the amino acid sequence of SEQ ID NO: 1 or a polynucleotide encoding the same as an active ingredient; and administering natural killer cells to a subject.
- the peptide having the amino acid sequence of SEQ ID NO: 1 of the present invention not only increases the cell killing ability of natural killer cells, but also reduces the increased homoeolysis by TGF- ⁇ , and further increases the sensitivity of natural killer cells to cancer cells. Even to improve, the peptide of the present invention can be usefully used as an active ingredient of an anticancer agent or an anticancer adjuvant.
- Figure 1 shows the results confirming that the cell killing ability of NK92 cells, which was reduced by TGF- ⁇ , was restored by treatment with a peptide consisting of the amino acid sequence of SEQ ID NO: 1.
- 1A is a diagram schematically illustrating the principle that the peptide exhibits an effect on natural killer cells, and B, C, and D are the cell killing ability of NK92 cells against lung cancer cell line H460, lung cancer cell line H3122, and blood cancer cell line K562, respectively. It shows the experimental result of measuring .
- Figure 2 shows the results confirming that the cell killing ability of primary NK cells reduced by TGF- ⁇ is restored by treatment with a peptide consisting of the amino acid sequence of SEQ ID NO: 1.
- 2A, B, and C show the experimental results of measuring the cell killing ability of primary NK cells for lung cancer cell line H460, lung cancer cell line H3122, and blood cancer cell line K562, respectively.
- Figure 3 is a view showing the reduction of the killing ability of NK92 for the lung cancer cell line H460 treated with TGF- ⁇ and the restoration of the reduced sensitivity by the peptide having the amino acid of SEQ ID NO: 1.
- Figure 3A is an explanatory diagram schematically showing the test of NK92 cell killing ability after treatment of lung cancer cell line H460 cells with TGF- ⁇
- Fig. 3B is an explanatory diagram schematically showing the test of NK92 cell killing ability when H460 cells are treated with TGF- ⁇ . decreased to less than half, and it was shown that the reduced killing activity was recovered by the peptide.
- FIG. 4 shows the results of confirming that Fratricide is increased between natural killer cells by TGF- ⁇ and Fratricide is decreased by the peptide having the amino acid of SEQ ID NO: 1.
- FIG. 4A schematically illustrates the effect of reducing the allokill of natural killer cells by using NK92 reacted with TGF- ⁇ as a target cell
- FIG. 4B and C show NK92 and primary NK cells, respectively. It is shown that the increase in homokilling of NK-92 cells in response to TGF- ⁇ and the decrease of homokilling by the peptide.
- FIG. 5 is a diagram showing that expression of TGF- ⁇ in lung cancer cells is inhibited by the peptide having the amino acid of SEQ ID NO: 1.
- FIG. 5A illustrates the effect of the peptide on reducing TGF- ⁇ expression in lung cancer cell line H460 cells
- FIG. 5B shows that the peptide reduces TGF- ⁇ expression in H460 cells.
- One aspect of the present invention provides a composition for enhancing the activity of natural killer cells.
- composition for enhancing the activity of natural killer cells of the present invention includes, as an active ingredient, a peptide having the amino acid sequence of SEQ ID NO: 1 or a functional equivalent thereof, or a polynucleotide encoding the peptide.
- the peptide may include the amino acid sequence of SEQ ID NO: 1 or a functional equivalent thereof, or may consist only of the amino acid sequence of SEQ ID NO: 1 or a functional equivalent thereof.
- a functional equivalent of the peptide is that some or all of the 13 amino acids constituting the amino acid sequence of SEQ ID NO: 1 are substituted with other amino acids, some of the 13 amino acids are deleted, or at least one of the 13 amino acids Amino acids of are added, or some or all of the 13 amino acids are modified, and may have the activity of a peptide having the amino acid sequence of SEQ ID NO: 1.
- the amino acid substitution may be a conservative substitution, for example, mutual substitution between aliphatic uncharged amino acids (Gly, Ala, Val, Leu, Ile), and mutual substitution between hydrophilic uncharged amino acids (Ser, Thr, Asn, Gln). , mutual substitution between aromatic amino acids (Phe, Tyr, Trp), mutual substitution between acidic amino acids (Asp, Glu), mutual substitution between basic amino acids (His, Lys, Arg), non-polar uncharged amino acids (Cys, Met) , Pro) and the like.
- Deletion or addition of the amino acid may occur, for example, in a part that is not directly involved in a part that does not affect the activity of the peptide having the amino acid sequence of SEQ ID NO: 1, and in particular, the addition of an amino acid is At least one amino acid may be inserted at the N-terminus or C-terminus as well as in the middle of the amino acid sequence of SEQ ID NO: 1.
- modification of the amino acid may be phosphorylation, acetylation, methylation, glycosylation, or the like, of some or all of the 13 amino acids constituting the amino acid sequence of SEQ ID NO: 1.
- the functional equivalent is one having at least 60% homology, at least 65%, at least 70%, at least 75%, at least 80% or at least 85%, for example at least 90% homology with the amino acid sequence of SEQ ID NO: 1. can
- the polynucleotide may encode the peptide, and may have, for example, a nucleotide sequence of SEQ ID NO: 2 or an equivalent nucleotide sequence.
- the equivalent nucleotide sequence is different from the nucleotide sequence of SEQ ID NO: 2, but means that the sequence of the encoding peptide is the same as the nucleotide sequence of SEQ ID NO: 2.
- the equivalent nucleotide sequence may have 60% or more homology, 70% or more, 80% or more, or 90% or more, for example, 95% or more homology with the nucleotide sequence of SEQ ID NO: 2.
- the polynucleotide may be included in a vector.
- the vector is preferably self-replicating, and more preferably capable of expressing the polynucleotide, such as a plasmid, cosmid, or phage.
- the vector containing the polynucleotide may be transformed into a host cell.
- the host cell is preferably capable of expressing a peptide having the amino acid sequence of SEQ ID NO: 1 or an equivalent thereof from the polynucleotide contained in the vector, and further secreting the expressed peptide to the outside of the cell may be more desirable.
- the natural killer cells are cytotoxic lymphocytes constituting a major component of the innate immune system, and are defined as large granular lymphocytes (LGL) and play an important role in the innate and adaptive immune systems.
- the natural killer cells may include natural killer progenitor cells as well as mature natural killer cells.
- the natural killer cells may be derived from mammals, and the mammals may be humans, monkeys, goats, sheep, rats, mice, etc., and in particular, humans, monkeys, or mice.
- the activity of the natural killer cells may be the ability to kill target cells such as cancer cells or virus-infected cells, degranulation of natural killer cells, stimulation of activating receptors of natural killer cells, or inactivation of inhibitory receptors,
- the activating receptors may be NKG2D, 2B4, DNAM-1, NCRs, and the like, and the inhibitory receptors PD-1, LAG-3, TIM-3, and the like.
- Improving the activity of natural killer cells may mean an increase in cytotoxicity of natural killer cells against target cells, a decrease in homoeostasis (fratricide), an improvement in sensitivity to target cells, and the like. there is.
- the increase in the cell killing ability of the natural killer cells may be an increase in the expression or secretion of substances involved in killing target cells, such as perforin, granzyme, and interferon, or including the above substances. It may be that the degranulation of the granules is increased.
- the perforin may be Perforin-1, Perforin-2, etc.
- the granzyme may be granzyme A, granzyme B, granzyme H, granzyme K, granzyme M, etc.
- the interferon may be interferon It may be a type 1 interferon such as - ⁇ , interferon- ⁇ , interferon- ⁇ , or interferon- ⁇ , a type 2 interferon such as interferon- ⁇ , or a type 3 interferon such as interferon-L1.
- the homokiller may mean that natural killer cells exhibit cell killing ability to each other, that is, a phenomenon in which natural killer cells themselves act as effector cells and target cells at the same time.
- Allokill among the natural killer cells can be increased by TGF- ⁇ , and the decrease in the homokiller of the natural killer cells means that the degree to which natural killer cells recognize other natural killer cells as target cells is reduced. .
- the improvement of the sensitivity of the natural killer cells to the target cells means that the natural killer cells can more easily recognize the target cells.
- the cell killing ability of lung cancer cell lines and blood cancer cell lines of NK92 or primary natural killer cells reduced by TGF- ⁇ is restored by treatment with a peptide consisting of the amino acid sequence of SEQ ID NO: 1 (see FIGS. 1 and 2), and the sensitivity of NK92 or primary natural killer cells reduced by TGF- ⁇ to lung cancer cell lines is restored (see FIG. 3), while natural killer cells increased by TGF- ⁇
- a peptide having the amino acid sequence of SEQ ID NO: 1 or a functional equivalent thereof or a polynucleotide encoding the peptide of the present invention can enhance the activity of natural killer cells It can be used as an active ingredient for
- another aspect of the present invention provides a method for enhancing the activity of natural killer cells, comprising the step of treating natural killer cells with the above-described peptide having the amino acid sequence of SEQ ID NO: 1 or a polynucleotide encoding the same.
- composition for enhancing the activity of natural killer cells may be used as an anticancer agent or an anticancer adjuvant. Therefore, another aspect of the present invention provides a pharmaceutical composition for preventing or treating cancer, wherein the pharmaceutical composition for preventing or treating cancer comprises a peptide having the amino acid sequence of SEQ ID NO: 1 or a functional equivalent thereof, or the peptide A polynucleotide encoding a may be included as an active ingredient.
- a peptide consisting of the amino acid sequence of SEQ ID NO: 1 when administered to an animal model transplanted with melanoma cells, the number of cancer nodules metastasizing to the lung is reduced compared to the negative control.
- Confirmed Bar (see FIG. 6), a peptide having the amino acid sequence of SEQ ID NO: 1 of the present invention or a functional equivalent thereof, or a polynucleotide encoding the peptide can be used as an active ingredient for preventing or treating cancer.
- the cancer generally refers to a physiological state of mammals characterized by unregulated cell growth, and abnormal proliferation occurs due to problems in the regulation function of normal division, differentiation, and death of cells, resulting in damage to surrounding tissues and organs. It refers to a state in which a lump is formed by infiltration and the existing structure is destroyed or transformed.
- the cancer may be solid cancer or metastatic cancer, such as colorectal cancer including colon cancer and rectal cancer, breast cancer, uterine cancer, cervical cancer, ovarian cancer, prostate cancer, brain tumor, head and neck carcinoma, melanoma, myeloma, leukemia, lymphoma, stomach cancer, lung cancer , pancreatic cancer, liver cancer, esophageal cancer, small intestine cancer, perianal cancer, fallopian tube carcinoma, endometrial carcinoma, vaginal carcinoma, vulvar carcinoma, Hodgkin's disease, bladder cancer, kidney cancer, ureteric cancer, renal cell carcinoma, renal pelvic carcinoma, bone cancer, skin cancer , head cancer, neck cancer, skin melanoma, intraocular melanoma, endocrine gland cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, central nervous system (CNS) tumor, primary CNS lymphoma .
- CNS central nervous system
- the prevention refers to any action that inhibits or delays the occurrence or progression of cancer, and the treatment includes not only the death of cancer cells, but also the reduction of growth of cancer cells, reduction of recurrence, anticancer activity of the immune system against cancer cells, and immunity. It refers to any effect in which cancer cells do not deteriorate further, such as memory formation or reduction of cancer cell invasion, but is not limited thereto.
- composition may further contain other active ingredients exhibiting anticancer activity.
- composition may further include a pharmaceutically acceptable carrier or additives in addition to the above active ingredients.
- the meaning of 'pharmaceutically acceptable means that it does not inhibit the activity of the active ingredient and does not have toxicity more than is adaptable to the subject of application (prescription).
- the carrier is defined as a compound that facilitates the addition of the compound into cells or tissues.
- the peptide having the amino acid sequence of SEQ ID NO: 1 or a functional equivalent thereof, or the polynucleotide encoding the peptide of the present invention can be administered alone or in combination with any convenient carrier, and such dosage forms can be administered single or repeated. It may be a dosage form.
- the composition may be a solid formulation or a liquid formulation. Solid preparations include, but are not limited to, powders, granules, tablets, capsules, and suppositories. Solid formulations may include carriers, flavoring agents, binders, preservatives, disintegrants, lubricants, fillers, and the like, but are not limited thereto.
- Liquid preparations include solutions, suspensions, and emulsions such as water and propylene glycol solutions, but are not limited thereto, and may be prepared by adding appropriate colorants, flavoring agents, stabilizers, viscosifiers, and the like.
- the powder contains a peptide having the amino acid sequence of SEQ ID NO: 1, which is an active ingredient of the present invention, or a functional equivalent thereof, or a polynucleotide encoding the peptide, and a suitable pharmaceutically acceptable carrier such as lactose, starch, or microcrystalline cellulose. It can be prepared by simple mixing.
- the granule is a peptide having the amino acid sequence of SEQ ID NO: 1 of the present invention or a functional equivalent thereof, or a polynucleotide encoding the peptide, a suitable pharmaceutically acceptable carrier, and pharmaceuticals such as polyvinylpyrrolidone, hydroxypropylcellulose, etc.
- a suitable pharmaceutically acceptable carrier such as water, ethanol, isopropanol, or the like
- a dry granulation method using compression force may be prepared by mixing the granules with a suitable pharmaceutically acceptable lubricant such as magnesium stearate and then tableting them using a tableting machine.
- a peptide having the amino acid sequence of SEQ ID NO: 1 or a functional equivalent thereof or a polynucleotide encoding the peptide of the present invention may be used as an oral agent or an injection (eg, intramuscular injection, intraperitoneal injection), depending on the disease to be treated and the condition of the individual. It may be administered by injection, intravenous injection, infusion, subcutaneous injection, implant), inhalant, nasal agent, vaginal agent, rectal agent, sublingual agent, transdermal agent, topical agent, etc., but is not limited thereto. Depending on the route of administration, it can be formulated into an appropriate dosage unit formulation containing a pharmaceutically acceptable carrier, excipients, and vehicles that are commonly used and non-toxic.
- the composition may be administered at about 0.0001 mg/kg to about 10 g/kg daily, and at a daily dosage of about 0.001 mg/kg to about 1 g/kg.
- the dosage may vary depending on the degree of purification of the mixture, the patient's condition (age, sex, weight, etc.), the severity of the condition being treated, and the like. If necessary, for convenience, the total daily dose may be administered in several divided doses throughout the day.
- another aspect of the present invention provides a cell therapy agent for preventing or treating cancer, including natural killer cells treated with a peptide having the amino acid sequence of SEQ ID NO: 1 or a polynucleotide encoding the same.
- cellular therapeutic agent refers to cells and tissues manufactured through isolation, culture, and special manipulation from an object, and is a drug (US FDA regulation) used for the purpose of treatment, diagnosis, and prevention.
- drug US FDA regulation
- living autologous, allogenic, and xenogenic cells are proliferated in vitro, selected, or the biological characteristics of cells are changed in other ways. Means medicines used for their intended purpose.
- a therapeutic agent used for the treatment of cancer refers to a therapeutic agent used for the treatment of cancer, and includes, as an active ingredient, a natural killer cell whose killing power against cancer cells is increased by treating a peptide having the amino acid sequence of SEQ ID NO: 1 described above or a polynucleotide encoding the same. It can be used as a cell therapy for the treatment and prevention of cancer.
- another aspect of the present invention is a pharmaceutical composition for preventing or treating cancer comprising, as an active ingredient, a peptide consisting of the amino acid sequence of SEQ ID NO: 1 or a polynucleotide encoding the above-described peptide, subject It provides a cancer treatment method comprising the step of administering to.
- Another aspect of the present invention also provides a method of treating cancer comprising the steps of:
- step (b) administering the natural killer cells of step (a) to a subject.
- the method of the present invention uses natural killer cells having increased killing power against cancer cells by treating the peptide of the present invention or a polynucleotide encoding the same, redundant descriptions thereof are omitted to avoid excessive complexity in the present specification.
- NK92 cells were cultured in ⁇ -MEM (Welgene) culture medium supplemented with 12.5% FBS (Fetal Bovine Serum, Corning, united states origin, 35-015-CV) and 12.5% horse serum (Gibco) in accordance with ATCC culture conditions in 0.2 mM M.I. Oinositol, 0.1 mM 2-mercaptoethanol, 0.02 mM folic acid, 1% antibiotics-antimycotic (Gibco) and IL-2 cytokine (Peprotech) were added at a concentration of 20 ng/ml and used as a culture medium. It was cultured in a 37 °C CO 2 incubator (water jacketed incubator, Thermo electron corporation) supplied with % CO 2 .
- the cells were cultured in a T-75 flask (Thermo) in 20-30 ml at a concentration of 1x10 5 cell/ml, and centrifuged at 1000 rpm for 5 minutes every 2-3 days with a Beckman Coulter to obtain the supernatant. After removal, the culture medium was exchanged.
- the CD3-separated cells were reacted with 10 ml of ACK buffer for 10 minutes to remove remaining red blood cells, and then washed twice using phosphate-buffered saline (PBS) supplemented with 2% FBS. Washing was carried out by centrifugation at 1500 rpm for 5 minutes in a Beckman Coulter to remove the supernatant. Using the cells thus obtained, culture was performed as natural killer cells.
- PBS phosphate-buffered saline
- the natural killer cell culture condition was 10 ng/ml IL-15 (Peprotech), 10 ng/ml IL-21 ( Peprotech), 10 -6 M hydrocortisone (Hydrocortisone, Peprotech) and 1% antibiotics-antimycotic (Gibco) were added and cultured.
- the cell culture concentration was cultured in a 6-well plate at a concentration of 2x10 6 cell / ml, and centrifuged with a centrifuge (Beckman Coulter) at 1200 rpm for 5 minutes every 2-3 days to remove the supernatant, and then exchange the culture medium. .
- FACS flow cytometry was performed by dispensing 2x10 4 cells into a FACS tube (Falcon), centrifuging with FBS-added PBS (FACS buffer) at 1500 rpm for 3 minutes in a centrifuge (Beckman Coulter), washing, and then removing the supernatant. Then, 100 ul of FACS buffer was added again to proceed.
- lung cancer cell lines H460 and H3122 were cultured and used as target cell lines.
- H460 and H3122 cells were cultured in RPMI (Welgene) supplemented with 10% FBS (Corning, united states origin, 35-015-CV) and 1% antibiotics-antimycotic (Gibco) was added according to ATCC culture conditions.
- the culture medium was used and cultured in a 37°C CO 2 incubator (water jacketed CO 2 incubator, Thermo electron corporation) supplied with 5% CO 2 .
- the cells were cultured at a concentration of 2x10 5 cell/ml in an amount of about 10 ml in a 100 mm x 20 mm cell culture dish (corning). Cells were observed and culture medium exchanged every 2-3 days.
- a hematological cancer cell line K562 was cultured and used as a target cell line.
- K562 cells were treated with 1% antibiotics-antimycotic (Gibco) in RPMI (Welgene) culture medium supplemented with 10% FBS (Fetal Bovine Serum, Corning, united states origin, 35-015-CV) according to ATCC culture conditions.
- the added culture medium was used and cultured in a 37°C CO 2 incubator (water jacketed CO 2 incubator, Thermo electron corporation) supplied with 5% CO 2 .
- the cells were cultured at a concentration of 2x10 5 cells/ml in about 20ml in a 75T Flask (corning). Culture medium was exchanged every 2-3 days.
- a peptide consisting of 13 amino acids of SEQ ID NO: 1 was synthesized by requesting Peptron Co., Ltd. (Peptron, Daejeon, Korea), and used in the following experiments.
- a TGF- ⁇ signal inhibitor was added to 1x10 5 cell/ml of NK92 cells or primary NK cells, respectively, at 37° C. for 2 hours After each incubation, 10 ng/ml of TGF- ⁇ was added and cultured again under the same conditions for 24 hours. Then, 20 ⁇ M of the peptide of Example [1-5] or 5 ⁇ M of SB431542 was added and cultured at 37° C. for 2 hours, then 10 ng/ml of TGF- ⁇ was added and cultured for 24 hours under the same conditions. . NK92 cells and primary NK cells cultured as described above were used as effector cells for the killing ability test.
- lung cancer cell lines H460 and H3122 cells and blood cancer cell line K562 were used as target cells for evaluating cell killing ability.
- Each of the H460, H3122 and K562 cell lines of 1x10 6 cells/ml was dyed by culturing at 37° C. for 1 hour with a culture solution supplemented with 5ul of calcein-AM (calcein-AM, invitrogen), followed by staining at 1000 rpm for 5 minutes. Washed by centrifugation.
- Example [2-2] Each of the target cells stained with calcein-AM in Example [2-2] was dispensed into a 96-well plate, and the effector cells prepared in Example [2-1] were treated.
- E: T ratio the ratio of effector cells and target cells
- E: T ratio The ratio was 10:1 and incubated at 37°C for 4 hours.
- the culture cultured as described above was centrifuged at 100 rcf for 5 minutes to separate the supernatant, which was dispensed in 100 ul each into a 96-well black plate, and then ELISA analysis was performed (fluorescence 480 nm / 530 nm, SpectraMax i3x Molecular Device). .
- the cell killing ability of NK92 cells was reduced by TGF- ⁇ for all three types of target cells, but the peptide of Example [1-5] or SB431542 reduced NK92 cells. It was confirmed that the cell killing ability of was restored again. In addition, the same effect of restoring the cell killing ability of natural killer cells by the peptides of Examples [1-5] was confirmed not only in NK92 cells, but also in primary NK cells as shown in FIG. 2.
- Each of the target cells stained with Calcein-AM as described above was dispensed into a 96-well plate, and fresh NK92 cells were used as the main effector cells and treated so that the E: T ratio was 20: 1, and 37 Incubated for 4 hours at °C.
- the culture cultured as described above was centrifuged at 100 rcf for 5 minutes to separate the supernatant, which was dispensed in 100 ul each on a 96-well black plate, and then ELISA analysis was performed (fluorescence 480 nm / 530 nm, SpectraMax i3x Molecular Device).
- Example [2-1] 1x10 6 cells/ml of NK92 cells cultured in the same manner as in Example [2-1], 5ul of calcein-AM (calcein-AM, invitrogen) was added to the culture medium at 37 °C 1 After staining by incubation for a period of time, the cells were washed by centrifugation at 1000 rpm for 5 minutes and prepared as 'target' cells. Each of the target cells stained with Calcein-AM as described above was dispensed into a 96-well plate, and fresh NK92 cells or primary NK cells were used as main effector cells, and the above Example [2-3] As in, it was treated at a ratio of 20:1 or 10:1 and incubated at 37°C for 4 hours.
- the culture cultured as described above was centrifuged at 100 rcf for 5 minutes to separate the supernatant, which was dispensed in 100 ul each into a 96-well black plate, and then ELISA analysis was performed (fluorescence 480 nm / 530 nm, SpectraMax i3x Molecular Device). .
- 2x10 5 cells / ml of lung cancer cell line H460 was cultured for 2 hours to stabilize it, and then treated with the peptides of Examples [1-5] at concentrations of 5 ⁇ M, 10 ⁇ M, and 20 ⁇ M, respectively, or SB431542 at a concentration of 5 ⁇ M , and cultured at 37° C. for 24 hours, then treated with the same concentration of the peptide or SB431542 of Example [1-5], and then cultured at 37° C. for 24 hours.
- the culture cultured as above was centrifuged at 100 rcf for 5 minutes to separate the supernatant and the pellet, and the supernatant was dispensed in 100 ul each on a 96-well black plate, and then ELISA analysis was performed (absorption 450 nm, SpectraMax i3x Molecular Device) The amount of secretion of TGF- ⁇ was measured.
- Example [1-5] In order to confirm the anticancer effect of the peptide prepared in Example [1-5] in vivo , 24-month-old C57BL6J mice were given 25 mg/kg of the peptide of Example [1-5] once a week. It was intraperitoneally administered 4 times for 4 weeks at intervals. Then, 4x10 5 B16F10 melanomas per mouse were administered through the tail vein, and the number of cancer nodules metastasized to the lungs was counted to confirm anticancer effects.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (14)
- 서열번호 1의 아미노산 서열을 갖는 펩타이드 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 포함하는 자연살해 세포의 활성 향상용 조성물.
- 청구항 1에 있어서,상기 펩타이드는 TGF-β의 발현 또는 활성을 억제하는 것인, 자연살해 세포의 활성 향상용 조성물.
- 청구항 2에 있어서,상기 펩타이드는 자연살해 세포의 세포 살상능을 향상시키는 것인, 자연살해 세포의 활성 향상용 조성물.
- 청구항 2에 있어서,상기 펩타이드는 자연살해 세포의 동종살해(fratricide) 활성을 감소시키는 것인, 자연살해 세포의 활성 향상용 조성물.
- 청구항 1에 있어서,상기 조성물은 항암제 또는 항암보조제인 것인, 자연살해 세포의 활성 향상용 조성물.
- 청구항 5에 있어서,상기 암은 고형암 또는 전이암인 것인, 자연살해 세포의 활성 향상용 조성물.
- 서열번호 1의 아미노산 서열로 이루어진 펩타이드 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물.
- 청구항 7에 있어서,상기 펩타이드는 상기 암에서 TGF-β의 발현 또는 활성을 억제하는 것인, 암의 예방 또는 치료용 약학적 조성물.
- 청구항 7에 있어서,상기 펩타이드는 상기 암의 암세포에 대한 자연살해 세포의 민감성(susceptibility)을 향상시키는 것인, 암의 예방 또는 치료용 약학적 조성물.
- 청구항 7에 있어서,상기 암은 TGF-β가 과발현 또는 과활성화된 것인, 암의 예방 또는 치료용 약학적 조성물.
- 서열번호 1의 아미노산 서열을 갖는 펩타이드 또는 이를 암호화하는 폴리뉴클레오티드를 처리한 자연살해 세포를 포함하는 암의 예방 또는 치료용 세포치료제.
- 서열번호 1의 아미노산 서열을 갖는 펩타이드 또는 이를 암호화하는 폴리뉴클레오티드를 자연살해 세포에 처리하는 단계를 포함하는 자연살해 세포의 활성 향상 방법.
- 서열번호 1의 아미노산 서열로 이루어진 펩타이드 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물을, 대상(subject)에게 투여하는 단계를 포함하는 암 치료 방법.
- 다음 단계를 포함하는 암 치료 방법:(a) 서열번호 1의 아미노산 서열로 이루어진 펩타이드 또는 이를 암호화하는 폴리뉴클레오티드를 자연살해 세포에 처리하는 단계; 및(b) 상기 (a) 단계의 자연살해 세포를 대상(subject)에게 투여하는 단계.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2022359191A AU2022359191A1 (en) | 2021-10-05 | 2022-10-05 | Composition for enhancing activity of natural killer cells |
CN202280067470.2A CN118103054A (zh) | 2021-10-05 | 2022-10-05 | 用于提高自然杀伤细胞的活性的组合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0131745 | 2021-10-05 | ||
KR1020210131745A KR20230048845A (ko) | 2021-10-05 | 2021-10-05 | 자연살해 세포의 활성 향상용 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023059064A1 true WO2023059064A1 (ko) | 2023-04-13 |
Family
ID=85803570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/014996 WO2023059064A1 (ko) | 2021-10-05 | 2022-10-05 | 자연살해 세포의 활성 향상용 조성물 |
Country Status (4)
Country | Link |
---|---|
KR (1) | KR20230048845A (ko) |
CN (1) | CN118103054A (ko) |
AU (1) | AU2022359191A1 (ko) |
WO (1) | WO2023059064A1 (ko) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100729283B1 (ko) * | 2005-06-08 | 2007-06-18 | 한국생명공학연구원 | Vdup1 단백질 또는 그를 코딩하는 유전자를유효성분으로 포함하는 자연살해세포 분화제 및 분화 방법 |
-
2021
- 2021-10-05 KR KR1020210131745A patent/KR20230048845A/ko not_active Application Discontinuation
-
2022
- 2022-10-05 CN CN202280067470.2A patent/CN118103054A/zh active Pending
- 2022-10-05 AU AU2022359191A patent/AU2022359191A1/en active Pending
- 2022-10-05 WO PCT/KR2022/014996 patent/WO2023059064A1/ko active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100729283B1 (ko) * | 2005-06-08 | 2007-06-18 | 한국생명공학연구원 | Vdup1 단백질 또는 그를 코딩하는 유전자를유효성분으로 포함하는 자연살해세포 분화제 및 분화 방법 |
Non-Patent Citations (4)
Title |
---|
CHOI, PYO: "New Treatment for Hepatocellular Carcinoma: Systemic Therapy", NATURAL KILLER CELL THERAPY. CLINICAL AND MOLECULAR HEPATOLOGY, vol. 14, no. 20, 2008, pages 49 - 52 * |
KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY: "Functional analysis of VDUP1 as a anti-cancer target", RESEARCH PROGRAM FOR NEW DRUG TARGET DISCOVERY PROJECT NO.: 20100020461, 1 January 2014 (2014-01-01), XP093055676, Retrieved from the Internet <URL:https://scienceon.kisti.re.kr/commons/util/orgDocDown.do?url=/tr_img/2014019/rttrko000000213323.pdf&ex=pdf&filename=항암제타겟으로서VDUP1의기능규명&cn=TRKO201400028407> [retrieved on 20230620] * |
LEE KN ET AL: "VDUP1 IS REQUIRED FOR THE DEVELOPMENT OF NATURAL KILLER CELLS", IMMUNITY, CELL PRESS, AMSTERDAM, NL, vol. 22, 1 February 2005 (2005-02-01), AMSTERDAM, NL , pages 195 - 208, XP008073880, ISSN: 1074-7613, DOI: 10.1016/j.immuni.2004.12.012 * |
ZHOU JIANBIAO; CHNG WEE-JOO: "Roles of thioredoxin binding protein (TXNIP) in oxidative stress, apoptosis and cancer", MITOCHONDRION, ELSEVIER, AMSTERDAM, NL, vol. 13, no. 3, 27 June 2012 (2012-06-27), NL , pages 163 - 169, XP028529911, ISSN: 1567-7249, DOI: 10.1016/j.mito.2012.06.004 * |
Also Published As
Publication number | Publication date |
---|---|
CN118103054A (zh) | 2024-05-28 |
AU2022359191A1 (en) | 2024-04-18 |
KR20230048845A (ko) | 2023-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Vujanovic et al. | Changes of liver-resident NK cells during liver regeneration in rats. | |
WO2018044105A1 (ko) | 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물 | |
WO2013100500A1 (ko) | 펩타이드, 5-플루오로우라실, 및 성숙수지상세포를 포함하는 암 치료용 약학적 조성물 | |
AU640954B2 (en) | Anti-tumor preparation comprising interleukin-2 and histamine, analogs thereof or H2-receptor agonists | |
WO2014157918A1 (ko) | 조절 t 세포로의 분화 유도 및 증식 촉진을 통한 면역 반응 억제용 약학 조성물 | |
WO2019124666A2 (ko) | 인터류킨-17 억제제 및 종양괴사인자-알파 억제제를 유효성분으로 포함하는 호중구성 폐 염증질환의 예방 또는 치료용 약학적 조성물 | |
Maestroni et al. | Melatonin and the immune-hematopoietic system therapeutic and adverse pharmacological correlates | |
WO2021210872A1 (ko) | 트롬빈 처리 줄기세포에서 유래된 엑소좀을 포함하는 당뇨병성 피부질환 예방 또는 치료용 조성물 | |
WO2011021833A2 (ko) | 염증 예방 또는 치료용 조성물 | |
WO2017146538A1 (ko) | 조절 t 세포 매개성 질환의 예방 또는 치료용 약학적 조성물 | |
WO2020045886A1 (ko) | 에리스로포이에틴 유래 펩티드를 함유하는 세포증식 촉진용 조성물 | |
WO2023059064A1 (ko) | 자연살해 세포의 활성 향상용 조성물 | |
WO2021150078A1 (ko) | Off-the-shelf 줄기세포 및 면역세포, 이를 포함하는 약학적 조성물 | |
WO2021206328A1 (ko) | 신규 재조합 엑소좀 및 그의 용도 | |
WO2017074118A1 (ko) | Foxp3를 발현하는 수지상 세포를 포함하는 면역 조절용 약학적 조성물 | |
KR20150112890A (ko) | Il―21을 발현하는 중간엽 줄기세포를 포함하는 b 세포 림프종 예방 또는 치료용 조성물 | |
WO2021177599A1 (en) | METHOD FOR PRODUCING MEMORY-LIKE NK CELLS WITH ABILITY TO EXPRESS HIGHER LEVELS OF NCRS, CYTOTOXICITY, AND IFN-γ THAN NK CELLS IN HUMAN PERIPHERAL BLOOD | |
Talpaz et al. | Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia | |
Rai et al. | New insights on stem cells modeling and treatment of human diseases | |
KR101432881B1 (ko) | 레티날 또는 레티노산을 유효성분으로 포함하는 자연살해세포의 독성 억제를 위한 세포보호용 조성물 | |
JP7488337B2 (ja) | Il-2タンパク質及びcd80タンパク質を含む融合タンパク質及びnk細胞を含む抗癌治療用組成物 | |
WO2020180065A1 (ko) | 제대혈 단핵세포에서의 자연살해세포의 제조 방법 | |
WO2020197296A1 (ko) | 플라젤린으로부터 유도된 tlr5 작용제를 유효성분으로 포함하는 이식편대숙주질환의 예방 또는 치료용 조성물 | |
Kalland | Physiology of natural killer cells. In vivo regulation of progenitors by interleukin 3. | |
Dubinett et al. | Adoptive immunotherapy of murine pulmonary metastases with interleukin 2 and interferon-gamma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22878885 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 23773162.5 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: AU2022359191 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2022359191 Country of ref document: AU Date of ref document: 20221005 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022878885 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022878885 Country of ref document: EP Effective date: 20240506 |